Next Article in Journal
Editorial of the Special Issue: Oncolytic Viruses as a Novel Form of Immunotherapy for Cancer
Next Article in Special Issue
BET Family Protein BRD4: An Emerging Actor in NFκB Signaling in Inflammation and Cancer
Previous Article in Journal
Aptamer Cell-Based Selection: Overview and Advances
Previous Article in Special Issue
Aspirin Prevention of Colorectal Cancer: Focus on NF-κB Signalling and the Nucleolus
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessReview
Biomedicines 2017, 5(3), 50;

Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity

Centre for Cell Signalling and Inflammation, Department of Medicine, Imperial College London, London W12 0NN, UK
Author to whom correspondence should be addressed.
Received: 30 June 2017 / Revised: 4 August 2017 / Accepted: 10 August 2017 / Published: 22 August 2017
(This article belongs to the Special Issue Roles of NF-κB in Cancer and Their Therapeutic Approaches)
Full-Text   |   PDF [3919 KB, uploaded 22 August 2017]   |  


Transcription factors of the nuclear factor κB (NF-κB) family are central coordinating regulators of the host defence responses to stress, injury and infection. Aberrant NF-κB activation also contributes to the pathogenesis of some of the most common current threats to global human health, including chronic inflammatory diseases, autoimmune disorders, diabetes, vascular diseases and the majority of cancers. Accordingly, the NF-κB pathway is widely considered an attractive therapeutic target in a broad range of malignant and non-malignant diseases. Yet, despite the aggressive efforts by the pharmaceutical industry to develop a specific NF-κB inhibitor, none has been clinically approved, due to the dose-limiting toxicities associated with the global suppression of NF-κB. In this review, we summarise the main strategies historically adopted to therapeutically target the NF-κB pathway with an emphasis on oncology, and some of the emerging strategies and newer agents being developed to pharmacologically inhibit this pathway. View Full-Text
Keywords: nuclear factor κB; NF-κB inhibitors; cancer; IκB kinase; Gadd45β; ubiquitin nuclear factor κB; NF-κB inhibitors; cancer; IκB kinase; Gadd45β; ubiquitin

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Printed Edition Available!
A printed edition of this Special Issue is available here.

Share & Cite This Article

MDPI and ACS Style

Begalli, F.; Bennett, J.; Capece, D.; Verzella, D.; D’Andrea, D.; Tornatore, L.; Franzoso, G. Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity. Biomedicines 2017, 5, 50.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top